Kong Ji Chuan, Zhou Feng, Shi Liting, Wei Yihui, Wu Chunhong
Henan Polytechinc University Jiaozuo Henan 45400 China
RSC Adv. 2024 Jul 5;14(30):21292-21299. doi: 10.1039/d4ra01611d.
Owing to the complexity of tumor treatment, clinical tumor treatment has evolved from a single treatment mode to multiple combined treatment modes. Reducing the tolerance of tumors to heat and the toxicity of chemotherapy drugs to the body, as well as increasing the sensitivity of tumors to photothermal therapy and chemotherapy drugs, are key issues that urgently need to be addressed in the current cancer treatment. In this work, polylactic acid-based drug nanoparticles (PLA@DOX/GA/ICG) were synthesized with good photothermal conversion ability by encapsulating the water-soluble anticancer drug doxorubicin (DOX), photothermal conversion agent indocyanine green (ICG) and liposoluble drug gambogic acid (GA) using a double emulsion method. The preparation process of PLA@DOX/GA/ICG was examined. Gambogic acid entrapped in PLA@DOX/GA/ICG nanoparticles could act as an HSP90 protein inhibitor to achieve bidirectional sensitization to chemotherapy and photothermal therapy under 808 nm laser irradiation for the first time, effectively ablating breast cancer cells . This nanodrug was expected to be used for the efficient treatment of tumors.
由于肿瘤治疗的复杂性,临床肿瘤治疗已从单一治疗模式发展为多种联合治疗模式。降低肿瘤对热的耐受性以及化疗药物对身体的毒性,同时提高肿瘤对光热疗法和化疗药物的敏感性,是当前癌症治疗中迫切需要解决的关键问题。在这项工作中,通过双乳液法将水溶性抗癌药物阿霉素(DOX)、光热转换剂吲哚菁绿(ICG)和脂溶性药物藤黄酸(GA)包裹起来,合成了具有良好光热转换能力的聚乳酸基药物纳米颗粒(PLA@DOX/GA/ICG)。研究了PLA@DOX/GA/ICG的制备过程。包裹在PLA@DOX/GA/ICG纳米颗粒中的藤黄酸可作为HSP90蛋白抑制剂,首次在808nm激光照射下实现对化疗和光热疗法的双向增敏,有效消融乳腺癌细胞。这种纳米药物有望用于肿瘤的高效治疗。